IMVARIA
IMVARIA Inc. is a software-as-medical-device (SaMD) company founded in 2019, specializing in AI-driven digital biomarker solutions for improving clinical decision-making. Their core products, Fibresolve and ScreenDx, leverage AI and machine learning to assist in the non-invasive diagnosis of lung diseases, particularly Interstitial Lung Disease (ILD) and Idiopathic Pulmonary Fibrosis (IPF). Fibresolve is FDA-authorized and designed to augment clinicians' assessments, while ScreenDx is FDA-cleared to automatically assess CT scans for ILD findings. The company's vision is to transform diagnosis into data science, potentially reducing the need for invasive procedures and optimizing patient outcomes. IMVARIA operates an AI Lab that processes clinical data, similar to a specialty lab, providing rapid analysis and reports.
IMVARIA
IMVARIA Inc. is a software-as-medical-device (SaMD) company founded in 2019, specializing in AI-driven digital biomarker solutions for improving clinical decision-making. Their core products, Fibresolve and ScreenDx, leverage AI and machine learning to assist in the non-invasive diagnosis of lung diseases, particularly Interstitial Lung Disease (ILD) and Idiopathic Pulmonary Fibrosis (IPF). Fibresolve is FDA-authorized and designed to augment clinicians' assessments, while ScreenDx is FDA-cleared to automatically assess CT scans for ILD findings. The company's vision is to transform diagnosis into data science, potentially reducing the need for invasive procedures and optimizing patient outcomes. IMVARIA operates an AI Lab that processes clinical data, similar to a specialty lab, providing rapid analysis and reports.